详情页

当前位置：首页 > 详情页

Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC

11| 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究参与人：

研究单位： [1]Betta Pharmaceuticals Co., Ltd. [2]Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences Beijing, Beijing, China, 100021 [3]Peking Union Medical College Hospital Beijing, Beijing, China, 100032 [4]Beijing Cancer Hospital Beijing, Beijing, China, 100142 [5]Fourth Hospital of Hebei Medical University Shijiazhuang, Hebei, China, 050011 [6]Affiliated Cancer Hospital of Harbin Medical University Harbin, Heilongjiang, China, 150081 [7]The First Hospital of China Medical University Shenyang, Liaoning, China, 110001 [8]The Second Affiliated Hospital of Anhui Medical University Hefei, Anhui, China, 230601

研究目的：

The main objective of this study is to evaluate the safety, tolerability, efficacy and pharmacokinetics of BPI-9016M in patients with c-Met-dysregulated advanced NSCLC. Biomarkers related to the efficacy of BPI-9016M will be investigated.